Monte Rosa Therapeutics (GLUE) drew fresh attention after reporting strong interim Phase 1 results for MRT-8102, its NEK7-directed molecular glue degrader. The data showed rapid, sustained reductions ...

As of Thursday, January 08, Monte Rosa Therapeutics, Inc.’s GLUE share price has surged by 8.03%, which has investors ...

Jefferies, TD Cowen and Piper Sandler are acting as joint book-running managers for the offering. Wedbush PacGrow and LifeSci Capital are acting as passive bookrunners for the offering.

Clinical-stage biotechnology company Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) on Wednesday revealed interim data from an ...

Jefferies, TD Cowen and Piper Sandler are acting as joint book-running managers for the offering. Wedbush PacGrow and LifeSci Capital are acting as passive bookrunners for this offering.

Monte Rosa Therapeutics (GLUE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term ...

Monte Rosa Therapeutics, Inc. ("Monte Rosa") (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines ...

Shares of Monte Rosa Therapeutics climbed after the company said its treatment for inflammatory diseases showed rapid and durable reductions in systemic inflation during an early-stage trial. The ...

Monte Rosa Therapeutics (GLUE) announced a public offering of 11,125,000 shares of its common stock at $24.00 each. It will ...

Shares of Monte Rosa Therapeutics climbed after the company said it will host a call Wednesday to review results from an early-stage trial of its treatment of inflammatory diseases. The stock rose 8.7 ...

Investing.com - Monte Rosa Therapeutics (NASDAQ:GLUE) received a reiterated Buy rating from TD Cowen on Wednesday following the company’s presentation of Phase 1 data for its NEK7 degrader. The stock, ...